IQVIA (IQV) News
NYSE: IQVHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
259.88+1.00 (+0.39%)
At close: Oct 9, 4:02 PM ET · Delayed 15 min
IQV news summary
We found 31 recent headlines mentioning IQVIA (IQV): 1 in the past week and 5 in the past 30 days, most often from Nasdaq, Seeking Alpha. For price context, IQV is up 0.39% at $259.88. The most recent story, "Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock", was published by Nasdaq on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest IQVIA headlines
- Here's Why IQVIA Holdings (IQV) is a Strong Momentum StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.Nasdaq
- Extensive Database & Solid Bookings Benefit IQVIA Amid Low LiquidityIQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.NasdaqIQV, PAYX, FISV
- IQVIA Holdings Now #239 Largest Company, Surpassing Vivmark ResidentialIn the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, IQVIA Holdings Inc (Symbol: IQV) has taken over the #239 spot from Vivmark Residential…NasdaqIQV, VMRK
- IQVIA Stock Rises 60% in 6 Months: Here's What You Should KnowIQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.NasdaqIQV, CNC, BTSG
- Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.NasdaqNPCE, IQV
- IQVIA prices $2B of senior notes due 2034Seeking Alpha
- VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate FastVeeva raises its fiscal 2027 outlook as Vault CRM adoption, R&D growth and Falcon AI momentum support expanding revenue and profitability.NasdaqVEEV, CRM, IQV
- Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.NasdaqTMDX, IQV
- Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.NasdaqIQV, EW
- Here's Why You Should Retain IQVIA Stock in Your Portfolio NowIQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.NasdaqIQV, GMED, CRBU
- Can AI Innovation and CRM Wins Boost Veeva Systems' Q2 Results?VEEV heads into Q2 with Falcon AI, Vault CRM wins and R&D Cloud growth in focus as revenue and EPS estimates point to double-digit gains.NasdaqVEEV, MEDP, IQV
- CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.NasdaqCRL, MEDP, IQV
- IQV Stock Gains 42% in 3 Months: Here's What You Should KnowIQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.NasdaqIQV, ANIK, BTSG
- Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- IQVIA Holdings (IQV) is a Top-Ranked Momentum Stock: Should You Buy?Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.NasdaqICLR, IQV, FTRE
- IQVIA: A Great Business At The Wrong Price (Rating Downgrade)Seeking Alpha
- IQVIA Holdings Inc. 2026 Q2 - Results - Earnings Call PresentationSeeking Alpha
- IQVIA Holdings Inc. (IQV) Q2 2026 Earnings Call TranscriptSeeking Alpha
- IQVIA Gears Up to Report Q2 Earnings: What's in the Offing?IQV heads into its Q2'26 earnings release with y/y revenue and EPS growth expected, supported by AI adoption, drug launches and high-margin segment gains.NasdaqIQV, WAT, ALC
- IQVIA Holdings Inc. (IQV) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- IQVIA: The Market May Be Missing The AI And Data StorySeeking Alpha
- IQVIA Holdings Inc. (IQV) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking AlphaIQV, BAC
- IQVIA Holdings Inc. 2026 Q1 - Results - Earnings Call PresentationSeeking Alpha
- IQVIA Holdings Inc. (IQV) Q1 2026 Earnings Call TranscriptSeeking Alpha
- IQVIA Holdings Inc. (IQV) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking AlphaIQV, BCS
- IQVIA Holdings Inc. (IQV) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha
- IQVIA Holdings: Still Exceeding Expectations As A Stealth CompounderSeeking Alpha
- IQVIA Holdings Inc. (IQV) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day TranscriptSeeking Alpha
- IQVIA Holdings Inc. (IQV) Q4 2025 Earnings Call TranscriptSeeking Alpha